Matches in Wikidata for { <http://www.wikidata.org/entity/Q66066043> ?p ?o ?g. }
Showing items 1 to 38 of
38
with 100 items per page.
- Q66066043 description "clinical trial" @default.
- Q66066043 description "ensayu clínicu" @default.
- Q66066043 description "klinisch onderzoek" @default.
- Q66066043 description "клінічне випробування" @default.
- Q66066043 description "կլինիկական փորձարկում" @default.
- Q66066043 name "Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2831781 After an Intravenous (IV) Dose in Healthy Japanese and Caucasian Subjects, and a Subcutaneous (SC) Dose in Healthy Caucasian Subjects" @default.
- Q66066043 name "Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2831781 After an Intravenous (IV) Dose in Healthy Japanese and Caucasian Subjects, and a Subcutaneous (SC) Dose in Healthy Caucasian Subjects" @default.
- Q66066043 type Item @default.
- Q66066043 label "Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2831781 After an Intravenous (IV) Dose in Healthy Japanese and Caucasian Subjects, and a Subcutaneous (SC) Dose in Healthy Caucasian Subjects" @default.
- Q66066043 label "Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2831781 After an Intravenous (IV) Dose in Healthy Japanese and Caucasian Subjects, and a Subcutaneous (SC) Dose in Healthy Caucasian Subjects" @default.
- Q66066043 prefLabel "Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2831781 After an Intravenous (IV) Dose in Healthy Japanese and Caucasian Subjects, and a Subcutaneous (SC) Dose in Healthy Caucasian Subjects" @default.
- Q66066043 prefLabel "Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2831781 After an Intravenous (IV) Dose in Healthy Japanese and Caucasian Subjects, and a Subcutaneous (SC) Dose in Healthy Caucasian Subjects" @default.
- Q66066043 P1132 Q66066043-56656301-1FBC-4699-B26E-BE3EF1C3DC69 @default.
- Q66066043 P1476 Q66066043-A02F0EC8-9A44-4FB0-8376-6A4250D0D596 @default.
- Q66066043 P17 Q66066043-AE1DC37F-05A1-419F-80A5-C2EA145110D3 @default.
- Q66066043 P2899 Q66066043-1A94918D-527C-405D-8AA4-11BE159FCA26 @default.
- Q66066043 P3098 Q66066043-FD98E389-58C2-41A5-9972-E55DFE695280 @default.
- Q66066043 P31 Q66066043-75F43EA0-8C6B-4FFD-9CD6-C004D7F4C3F6 @default.
- Q66066043 P4135 Q66066043-99F4A3F8-5BE9-4F9C-800E-0DC83F81E6C8 @default.
- Q66066043 P580 Q66066043-D52E3A49-7684-424B-97FF-87BFA32F36E3 @default.
- Q66066043 P582 Q66066043-ED980F5C-7B19-4D52-BC74-9195FD972E15 @default.
- Q66066043 P6099 Q66066043-231B2531-3B5E-4F6E-A5DD-0CB9CE445038 @default.
- Q66066043 P6153 Q66066043-830C0FFB-9DA3-41DC-B6CA-EDA7E0F23C7F @default.
- Q66066043 P8363 Q66066043-8F066685-E95B-4687-B747-5FC666793696 @default.
- Q66066043 P859 Q66066043-5F37A467-09ED-4B33-BAA9-2E7EE3E64C22 @default.
- Q66066043 P1132 "+36" @default.
- Q66066043 P1476 "A Randomised, Double-blind, Placebo-controlled Phase I Study of the Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Intravenous Dose of GSK2831781 in Healthy Japanese and Caucasian Participants, and a Single Subcutaneous Dose of GSK2831781 in Healthy Caucasian Participants" @default.
- Q66066043 P17 Q145 @default.
- Q66066043 P2899 "+18" @default.
- Q66066043 P3098 "NCT03965533" @default.
- Q66066043 P31 Q30612 @default.
- Q66066043 P4135 "+65" @default.
- Q66066043 P580 "2019-06-10T00:00:00Z" @default.
- Q66066043 P582 "2020-01-21T00:00:00Z" @default.
- Q66066043 P6099 Q5452194 @default.
- Q66066043 P6153 Q212322 @default.
- Q66066043 P8363 Q78089383 @default.
- Q66066043 P859 Q212322 @default.